Ologen Implant Versus Mitomycin C in Combined Trabeculectomy and Phacoemulsification

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2022 Mar 25

PMID 35326026

Authors

Chandrima Paul

J Divya

Richa Kamal

Anujeet Paul

Affiliations

Soon will be listed here.

Abstract

Purpose: To comparatively evaluate in Indian eyes with coexisting cataract and primary open-angle glaucoma the outcome of mitomycin C (MMC) and Ologen implant as adjunctives in combined phacoemulsification with trabeculectomy.

Methods: Eyes with primary open-angle glaucoma that underwent trabeculectomy and phacoemulsification with IOL implantation with either MMC application or Ologen implant between June 2019 and February 2020 were followed up for 12 months. Thirty-four eyes of 34 participants were studied. The primary outcome was intraocular pressure (IOP), and the secondary outcomes were the number of ocular hypotensives, best distance visual acuity (BDVA), and bleb morphology.

Results: In 16 eyes treated with MMC and 18 eyes treated with Ologen implant, it was observed that the mean postoperative IOP (14.62 ± 2.89 mm Hg with MMC and 14.56 ± 4.14 mm Hg with Ologen implant) was not significantly different in both groups (P = 0.47). Number of ocular hypotensives and BDVA were also comparable between the two groups. However, bleb morphology was better with Ologen implantation. One eye in the MMC group developed hypotony which was conservatively managed.

Conclusion: MMC and Ologen are both effective adjunctives in combined phaco-trabeculectomy. However, the Ologen implant provides better bleb health and safety.

References

El-Sayyad F, Ahmed El-Saied H, Abdelhakim M . Trabeculectomy with Ologen versus Mitomycin C in Juvenile Open-Angle Glaucoma: A 1-Year Study. Ophthalmic Res. 2017; 57(4):230-238. DOI: 10.1159/000456719. View

Stavrakas P, Georgopoulos G, Milia M, Papaconstantinou D, Bafa M, Stavrakas E . The use of amniotic membrane in trabeculectomy for the treatment of primary open-angle glaucoma: a prospective study. Clin Ophthalmol. 2012; 6:205-12. PMC: 3280101. DOI: 10.2147/OPTH.S27187. View

Razeghinejad M, Fudemberg S, Spaeth G . The changing conceptual basis of trabeculectomy: a review of past and current surgical techniques. Surv Ophthalmol. 2011; 57(1):1-25. DOI: 10.1016/j.survophthal.2011.07.005. View

Sihota R, Angmo D, Ramaswamy D, Dada T . Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018; 66(4):495-505. PMC: 5892050. DOI: 10.4103/ijo.IJO_1130_17. View

Debry P, Perkins T, Heatley G, Kaufman P, Brumback L . Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002; 120(3):297-300. DOI: 10.1001/archopht.120.3.297. View

Ji Q, Qi B, Liu L, Guo X, Zhong J . Efficacy and Safety of Ologen Implant Versus Mitomycin C in Primary Trabeculectomy: A Meta-analysis of Randomized Clinical Trials. J Glaucoma. 2014; 24(5):e88-94. DOI: 10.1097/IJG.0000000000000147. View

Slabaugh M, Bojikian K, Moore D, Chen P . The effect of phacoemulsification on intraocular pressure in medically controlled open-angle glaucoma patients. Am J Ophthalmol. 2013; 157(1):26-31. DOI: 10.1016/j.ajo.2013.08.023. View

Lockwood A, Brocchini S, Khaw P . New developments in the pharmacological modulation of wound healing after glaucoma filtration surgery. Curr Opin Pharmacol. 2012; 13(1):65-71. DOI: 10.1016/j.coph.2012.10.008. View

Lama P, Fechtner R . Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48(3):314-46. DOI: 10.1016/s0039-6257(03)00038-9. View

10.

Chen H, Ritch R, Krupin T, Hsu W . Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci. 2006; 47(12):5310-4. DOI: 10.1167/iovs.06-0378. View

11.

Husain R, Clarke J, Seah S, Khaw P . A review of trabeculectomy in East Asian people--the influence of race. Eye (Lond). 2004; 19(3):243-52. DOI: 10.1038/sj.eye.6701477. View

12.

Derick R, Pasquale L, Quigley H, Jampel H . Potential toxicity of mitomycin C. Arch Ophthalmol. 1991; 109(12):1635. DOI: 10.1001/archopht.1991.01080120013002. View

13.

Dietlein T, Lappas A, Rosentreter A . Secondary subconjunctival implantation of a biodegradable collagen-glycosaminoglycan matrix to treat ocular hypotony following trabeculectomy with mitomycin C. Br J Ophthalmol. 2013; 97(8):985-8. DOI: 10.1136/bjophthalmol-2013-303357. View

14.

Rosentreter A, Schild A, Jordan J, Krieglstein G, Dietlein T . A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma. Eye (Lond). 2010; 24(9):1449-57. DOI: 10.1038/eye.2010.106. View

15.

Wang W, Zhou M, Huang W, Zhang X . Ex-PRESS implantation versus trabeculectomy in uncontrolled glaucoma: a meta-analysis. PLoS One. 2013; 8(5):e63591. PMC: 3669314. DOI: 10.1371/journal.pone.0063591. View

16.

Wells A, Crowston J, Marks J, Kirwan J, Smith G, Clarke J . A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma. 2004; 13(6):454-60. DOI: 10.1097/00061198-200412000-00005. View

17.

Papaconstantinou D, Georgalas I, Karmiris E, Diagourtas A, Koutsandrea C, Ladas I . Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol. 2009; 88(1):80-5. DOI: 10.1111/j.1755-3768.2009.01753.x. View

18.

Varma R, Lee P, Goldberg I, Kotak S . An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011; 152(4):515-22. PMC: 3206636. DOI: 10.1016/j.ajo.2011.06.004. View

19.

Hsu W, Spilker M, Yannas I, Rubin P . Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000; 41(9):2404-11. View

20.

Boey P, Narayanaswamy A, Zheng C, Perera S, Htoon H, Tun T . Imaging of blebs after phacotrabeculectomy with Ologen collagen matrix implants. Br J Ophthalmol. 2010; 95(3):340-4. DOI: 10.1136/bjo.2009.177758. View